Event

Economic Impact of Implementing a National Serialization and Traceability System

2:30 PM - 3:30 PM on Tuesday, Apr 23, 2013


Description: Lawmakers are considering a federal standard to improve the security of drug distribution and reduce the risk of counterfeit and diverted medicines entering the legitimate pharmaceutical supply chain. However, they are...
Ernst--Young--Black--_178612

Ernst & Young’s Beyond Borders Report 2013

10:00 AM - 11:30 AM on Tuesday, Apr 23, 2013


Description: The business climate for the biotechnology industry remains challenging. In today’s “new normal,” venture capitalists are more selective, IPOs more elusive and alliance partners more demanding. And even as biotech companies...
Event

Going on the Offense: Proactive Strategies to Reduce Uncertainty

9:00 AM - 10:15 AM on Wednesday, Apr 24, 2013


Description: Bioengineered agricultural and animal products for food and for the production of biofuels have become a focus of opposition groups through frequent litigation, regulatory advocacy and negative media strategies. This...
Event

Navigating the Special Challenges of Commercializing Biologics for Rare Diseases: Distribution, Partnership, Reimbursement

3:45 PM - 5:00 PM on Tuesday, Apr 23, 2013


Description: Manufacturers of biologics for rare diseases face unique commercialization challenges at odds with the model of low-cost, bulk product distribution. Information is key down the line: patients and advocates need guidance...
Event

Spotlight on Malaysia: BioMedical (Biopharma) Hub for the Emerging Markets

11:00 AM - 11:45 AM on Monday, Apr 22, 2013


Description: An emerging market, Malaysia is the 3rd largest economy in Southeast Asia and one of the best economic records in Asia as a newly industrialized country. Malaysia aims to become a...
Campbell%20Alliance%20w_111075.o_111075.%20tag-%204_111075.5_111075.10_111075

The Return of the Pipeline Deal

2:00 PM - 3:30 PM on Wednesday, Apr 24, 2013


Description: Since 2007 we have seen a decline in the pipeline deals across biotech. It used to be common to read about the next billion dollar biobuck deal that your neighborhood small...